Merck Highlights Infectious Disease Advances at IDWeek 2024
Key Insights
Merck (search) will present Phase 2b/3 trial results for clesrovimab, a preventative monoclonal antibody against respiratory syncytial virus (search) (RSV (search)) in infants.
Data from the Phase 3 STRIDE-8 trial of CAPVAXIVE, a pneumococcal 21-valent conjugate vaccine, in adults at increased risk of pneumococcal disease (search) will be shared.
Week 48 data from a Phase 2 study of a once-weekly oral combination of islatravir and lenacapavir for HIV-1 (search) treatment will be presented.
Merck (search) is set to present new research findings at IDWeek 2024, showcasing its diverse portfolio and pipeline in vaccines and infectious diseases. The data, spanning RSV (search), pneumococcal disease (search), and HIV, will be presented in Los Angeles, CA, from October 16-19.
Clesrovimab for RSV Prevention in Infants
Detailed results from the Phase 2b/3 trial of clesrovimab (MK-1654), an investigational prophylactic monoclonal antibody for infants, will be highlighted. Clesrovimab is designed to prevent respiratory syncytial virus (search) (RSV (search)) disease. The study evaluated a single dose of clesrovimab in pre-term and full-term infants.
Additionally, the first presentation of results from the interim analysis of the Phase 3 trial evaluating the safety and efficacy of clesrovimab versus palivizumab in infants and children at increased risk for severe RSV (search) disease will be presented.
CAPVAXIVE for Pneumococcal Disease in Adults
Merck (search) will also present data from the Phase 3 STRIDE-8 trial evaluating CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) in vaccine-naïve adults aged 18-64 years at increased risk of pneumococcal disease (search). CAPVAXIVE is designed to address Streptococcus pneumoniae serotypes predominantly responsible for adult invasive pneumococcal disease (IPD).
Islatravir and Lenacapavir for HIV-1 Treatment
Week 48 data from the Phase 2 study evaluating a once-weekly oral combination regimen of islatravir, Merck (search)’s nucleoside reverse transcriptase translocation inhibitor (NRTTI), and Gilead’s lenacapavir, a first-in-class capsid inhibitor, for the treatment of people with HIV-1 (search) infection will be shared.
Broader Portfolio Data
Further data includes findings from the SPECTRA (Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam [C/T] Real-world Analysis) study and updates from the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance program.
"The breadth of innovative research we will showcase during IDWeek 2024 is a testament to our ongoing commitment to advancing science with the pursuit of addressing persisting global health needs, such as RSV (search)," said Dr. Paula Annunziato, senior vice president, infectious diseases and vaccines, Global Clinical Development, Merck (search) Research Laboratories. "We are proud of our company’s longstanding legacy and continued momentum in helping to treat and prevent a variety of potentially serious infectious diseases for individuals around the world and across all stages of life – from birth through older adulthood – and we look forward to sharing these data."